Galiè 2016a.

Methods	Randomised double‐blind controlled trial Mean duration of follow‐up 4.7 months
Participants	Inclusion criteria: Consecutive naïve patients with operable and non‐operable chronic thromboembolic pulmonary hypertension (WHO Group 4) n = 121
Interventions	Sildenafil (20 mg 3 times ar day) (N=61) versus bosentan (125 mg bid) (N=60)
Outcomes	6MWD RAP Mean PAP CI PVR Adverse events
Notes	Abstract only States the abstract is funded by "none" Location of trial and dates of enrolment not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Random sequence generation was not reported, although information given was limited as this was an abstract only. We contacted the authors but there was no reply at the time of publication
Allocation concealment (selection bias)	Unclear risk	Allocation concealment was not reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Blinding of participants and personnel was not reported
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of outcome assessment was not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	It was not clear if there were issues with attrition bias
Selective reporting (reporting bias)	Unclear risk	It is not clear if there was selective reporting bias
Other bias	Unclear risk	Unclear if other bias is present ‐ abstract only from conference proceedings